Phaseline

Companies › Great Novel Therapeutics Biotech & Medicals

Great Novel Therapeutics Biotech & Medicals: clinical trials, targets and expected readouts

1 active drug program in 20 registered trials: 12 Phase 2, 6 Phase 1, 2 Phase 3; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Chidamide
Histone deacetylase (HDAC) inhibitor
HDAC (class I/II)Phase 2Relapsed or Refractory Peripheral T-cell Lymphoma; Metastatic Microsatellite-stable Colorectal Cancer; Diffuse Large B-Cell Lymphoma (DLBCL); Colorectal Cancer Metastatic …Jun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06685276ChidamidePhase 2Colorectal Cancer MetastaticOncologyDec 2026
NCT05958719ChidamidePhase 2Peripheral T Cell LymphomaOncologyDec 2026
NCT06451861ChidamidePhase 2Acute Myeloid LeukemiaOncologyDec 2026
NCT06764017ChidamidePhase 2Diffuse Large B-Cell LymphomaOncologyDec 2026
NCT07304232ChidamidePhase 2Allogeneic Hematopoietic Cell Transplantation (HCT)OncologyDec 2026
NCT05682755ChidamidePhase 1Leukemia, Myeloid, AcuteOncologyDec 2026
NCT05768503ChidamidePhase 3Metastatic Microsatellite-stable Colorectal CancerOncologyJan 2027
NCT05833724ChidamidePhase 2Relapsed or Refractory Peripheral T-cell LymphomaOncologyJun 2027
NCT07545967ChidamidePhase 1Head and Neck Squamous Cell Carcinoma HNSCCOncologyJul 2027
NCT07093710ChidamidePhase 1Peripheral T Cell LymphomaOncologyAug 2027
NCT03031262ChidamidePhase 1AMLOncologyDec 2027
NCT07538180ChidamidePhase 2Newly Diagnosed MYC/BCL2 Double-expressor DLBCLOncologyDec 2027
NCT05270200ChidamidePhase 1Leukemia, Myeloid, AcuteOncologyDec 2027
NCT07518602ChidamidePhase 2Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)OncologyMar 2028
NCT07058103ChidamidePhase 2Angioimmunoblastic T-Cell Lymphoma RecurrentOncologyApr 2028
NCT07168317ChidamidePhase 2New Diagnosed Angioimmunoblastic T-Cell LymphomaOncologyAug 2028
NCT07754890ChidamidePhase 1Cutaneous T-cell Lymphoma (CTCL)OncologyDec 2028
NCT07507318ChidamidePhase 2Diffuse Large B-Cell LymphomaOncologyJun 2029
NCT07493109ChidamidePhase 3Diffuse Large B-Cell Lymphoma (DLBCL)OncologySep 2029
NCT07493148ChidamidePhase 2Diffuse Large B-Cell Lymphoma (DLBCL)OncologyDec 2029

Targets

HDAC (class I/II) (1)

Companies with the same targets

Xynomic Pharmaceuticals Jubilant Therapeutics Unravel Biosciences Italfarmaco Daiichi Sankyo Chengdu Zenitar Biomedical Technology Acrotech Biopharma Novelwise Pharmaceutical Chipscreen Biosciences Novartis

Companies built like this

Italfarmaco Acrotech Biopharma Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.